Research programme: urotensin-II receptor antagonists - Johnson and Johnson

Drug Profile

Research programme: urotensin-II receptor antagonists - Johnson and Johnson

Alternative Names: JNJ-39319202; JNJ-39327041

Latest Information Update: 16 Dec 2010

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Isoindoles; Piperazines
  • Mechanism of Action Urotensin II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic heart failure

Most Recent Events

  • 16 Dec 2010 No development reported for Chronic heart failure in USA (unspecified route)
  • 21 Aug 2008 Early research in Chronic heart failure in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top